

DAFTAR PUSTAKA

- Accapezzato, D, Caccavale, R, Paroli, MP, Gioia, C, Nguyen, BL, Spadea, L & Paroli, M 2023, "Advances in the pathogenesis and treatment of systemic lupus erythematosus," *International Journal of Molecular Sciences*, 24(7):6578, <https://www.mdpi.com/1422-0067/24/7/6578>.
- Almaani, S, Meara, A & Rovin, BH 2016, "Update on Lupus nephritis," *Clinical Journal of the American Society of Nephrology*, 12(5):825–835, <https://doi.org/10.2215/cjn.05780616>.
- Anders, H-J, Loutan, J, Bruchfeld, A, Fernández-Juárez, GM, Floege, J, Goumenos, D, Turkmen, K, Van Kooten, C, Frangou, E, Stevens, KI, Kronbichler, A, Segelmark, M & Tesar, V 2021, "The management of lupus nephritis as proposed by EULAR/ERA 2019 versus KDIGO 2021," *Nephrology Dialysis Transplantation*, 38(3):551–561, <https://doi.org/10.1093/ndt/gfab351>.
- Burmester, G.-R. et al. (2003) Color atlas of immunology. Stuttgart: Thieme.
- Cameron, JS 1992, "Prediction of outcome in lupus nephritis," *Lupus*, 1(4):197, <https://doi.org/10.1177/096120339200100401>.
- Carmier, D, Marchand-Adam, S, Diot, P & Diot, E 2010, "Respiratory involvement in systemic lupus erythematosus," *Revue Des Maladies Respiratoires*, 27(8):e66–e78, <https://doi.org/10.1016/j.rmr.2010.01.003>.
- Cervera, R, Khamashta, MA, Font, J, Sebastiani, GD, Gil, A, Lavilla, P, Mejía, JC, Aydintug, AO, Chwalinska-Sadowska, H, De Ramón, E, Fernández-Nebro, A, Galeazzi, M, Valen, M, Mathieu, A, Houssiau, F, Caro, N, Alba, P, Ramos-Casals, M, Ingelmo, M & Hughes, GRV 2003, "Morbidity and mortality in systemic lupus erythematosus during a 10-Year period," *Medicine*, 82(5):299–308, <https://doi.org/10.1097/01.md.0000091181.93122.55>.
- Chatham, WW & Kimberly, RP 2001, "Treatment of lupus with corticosteroids," *Lupus*, 10(3):140–147, <https://doi.org/10.1191/096120301675075008>.
- Dahlan, M.S., 2013. Besar Sampel dan Cara Pengambilan Sampel, Tiga. ed. Salemba Medika, Jakarta.
- D'Cruz, DP, Khamashta, MA & Hughes, GR 2007, "Systemic lupus erythematosus," *The Lancet*, 369(9561):587–596, [https://doi.org/10.1016/s0140-6736\(07\)60279-7](https://doi.org/10.1016/s0140-6736(07)60279-7).
- Elera-Fitzcarrald, C, Fuentes, A, González, LA, Burgos, PI, Alarcón, GS & Ugarte-Gil, MF 2018b, "Factors affecting quality of life in patients with systemic lupus erythematosus: important considerations and potential interventions," *Expert Review of Clinical Immunology*, 14(11):915–931, <https://doi.org/10.1080/1744666x.2018.1529566>.
- Elhefny, AM, Farouk, HM, El-Azizi, NO, Elzaher, AA & Mohammed, ES 2018, "Hazards of pulse steroid use in a cohort of Egyptian lupus nephritis patients," *The Egyptian Rheumatologist*, 41(4):277–281, <https://doi.org/10.1016/j.ejr.2018.12.001>.

- Frangou, EA, Bertsias, G & Boumpas, DT 2016, “Cytotoxic-Immunosuppressive drug treatment,” in *Elsevier eBooks*, pp. 533–541, <https://doi.org/10.1016/b978-0-12-801917-7.00062-0>.
- Isbagio, H., Albar, Z., Kasjmir, Y., 2009. Lupus Eritematosus Sistemik, Ilmu Penyakit Dalam Jilid III. Edisi kelima. Interna Publishing, Jakarta.
- Kamen, DL & Strange, C 2010, “Pulmonary manifestations of systemic lupus erythematosus,” *Clinics in Chest Medicine*, 31(3):479–488, <https://doi.org/10.1016/j.ccm.2010.05.001>.
- Kasjmir, Y.I., Handono, K., Wijaya, L.K., Hamijoyo, L., Albar, Z., et al, 2011. Rekomendasi Perhimpunan Rheumatologi Indonesia untuk Diagnosis dan Pengelolaan Sistemik Lupus Eritematosus.
- Kasturi, S & Sammaritano, LR 2015, “Corticosteroids in lupus,” *Rheumatic Disease Clinics of North America*, 42(1):47–62, <https://doi.org/10.1016/j.rdc.2015.08.007>.
- Kim, J-W, Kim, H-A, Suh, C-H & Jung, J-Y 2022, “Sex hormones affect the pathogenesis and clinical characteristics of systemic lupus erythematosus,” *Frontiers in Medicine*, 9, <https://doi.org/10.3389/fmed.2022.906475>.
- Lehman TJA, Mouradian JA., 1999, Systemic lupus erythematosus. In: Barratt TM, Avner ED, Harman WE (eds) Pediatric nephrology. Lippincott Williams and Wilkins, Baltimore, pp 793–810
- Mahajan, A, Amelio, J, Gairy, K, Kaur, G, Levy, RA, Roth, D & Bass, D 2020, “Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression,” *Lupus*, 29(9):1011–1020, <https://doi.org/10.1177/0961203320932219>.
- Murphy, G & Isenberg, DA 2019, “New therapies for systemic lupus erythematosus — past imperfect, future tense,” *Nature Reviews Rheumatology*, 15(7):403–412, <https://doi.org/10.1038/s41584-019-0235-5>.
- Musa R., Brent L. H., & Qurie, A., 2019, *Lupus Nephritis*. PubMed, StatPearls. <https://www.ncbi.nlm.nih.gov/books/NBK499817/>
- Perhimpunan Rheumatologi Indonesia, 2019. Rekomendasi perhimpunan Rheumatologi Indonesia untuk diagnosis dan pengelolaan Lupus Eritematosus Sistemik. Perhimpunan Rheumatologi Indonesia, Jakarta.
- Puapatanakul, P, Chansritrakul, S, Susantitaphong, P, Ueaphongsukkit, T, Eiam-Ong, S, Praditpornsilpa, K, Kittanamongkolchai, W & Avihingsanon, Y 2019, “Interferon-Inducible Protein 10 and Disease Activity in Systemic lupus erythematosus and lupus nephritis: A Systematic Review and Meta-Analysis,” *International Journal of Molecular Sciences*, 20(19):4954, <https://doi.org/10.3390/ijms20194954>.
- Pons-Estel, GJ, Ugarte-Gil, MF & Alarcón, GS 2017, “Epidemiology of systemic lupus erythematosus,” *Expert Review of Clinical Immunology*, 13(8):799–814, <https://doi.org/10.1080/1744666x.2017.1327352>.
- Pusdatin, 2017. Situasi Lupus di Indonesia. Pusat data dan informasi kementerian kesehatan Indonesia, Jakarta.

- Rovin, BH, Teng, YKO, Ginzler, EM, Arriens, C, Caster, DJ, Romero-Diaz, J, Gibson, K, Kaplan, J, Lisk, L, Navarra, S, Parikh, SV, Randhawa, S, Solomons, N & Huizinga, RB 2021b, "Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial," *The Lancet*, 397(10289):2070–2080, [https://doi.org/10.1016/s0140-6736\(21\)00578-x](https://doi.org/10.1016/s0140-6736(21)00578-x).
- Ruiz-Irastorza, G, Ugarte, A, Terrier, CS-P, Lazaro, E, Iza, A, Couzi, L, Saenz, R, Richez, C, Porta, S & Blanco, P 2017, "Repeated pulses of methyl-prednisolone with reduced doses of prednisone improve the outcome of class III, IV and V lupus nephritis: An observational comparative study of the Lupus-Cruces and lupus-Bordeaux cohorts," *Autoimmunity Reviews*, 16(8):826–832, <https://doi.org/10.1016/j.autrev.2017.05.017>.
- Scheinberg, M 2016, "The history of pulse therapy in lupus nephritis (1976–2016)," *Lupus Science & Medicine*, 3(1):e000149, <https://doi.org/10.1136/lupus-2016-000149>.
- Stanova, AK, Ryabkova, VA, Tillib, SV, Utekhin, VJ, Churilov, LP & Shoenfeld, Y 2020, "Anti-Idiotypic Agonistic Antibodies: Candidates for the role of universal Remedy," *Antibodies*, 9(2):19, <https://doi.org/10.3390/antib9020019>.
- Sunarso, I, Setiani, A, Nurudhin, A & Werdiningsih, Y 2023, "LP-070 Medication compliance in systemic lupus erythematosus: community-based study in Surakarta, Indonesia," *SLE Epidemiology and Public Health*, A115.2-A115, <https://doi.org/10.1136/lupus-2023-kcr.181>.
- Touma, Z., Gladman, D.D., Urowitz, M.B., 2013. 'Clinical Measures, Metrics, and Indices,' in: Dubois' Lupus Erythematosus and Related Syndromes: Eighth Edition. Elsevier Inc, pp. 563–581.
- Zickert, A, Sundelin, B, Svenungsson, E & Gunnarsson, I 2014, "Role of early repeated renal biopsies in lupus nephritis," *Lupus Science & Medicine*, 1(1):e000018, <https://doi.org/10.1136/lupus-2014-000018>.